Overview of Indium

Property	Description
Active ingredient	Indium (^111In) Oxyquinoline
Form	Sterile Solution (Injectable)
Pharmacological class	Diagnostic Radiopharmaceutical
Common use	Localization of inflammatory processes
Origin	Synthetic radiochemical chelated complex

What is Indium (^111In) Oxyquinoline and Its Classification?

Indium (^111In) Oxyquinoline is strictly defined as a Diagnostic Radiopharmaceutical, a specialized synthetic agent used exclusively within the field of Nuclear Medicine to aid in diagnosis, not to provide therapeutic treatment. It belongs to the official pharmacological class of Radioactive Diagnostic Agents, reflecting its function to emit signals for imaging rather than affecting physiological change. This agent is clinically recognized for providing essential diagnostic information in complex medical scenarios where other imaging modalities may be insufficient. The product is prepared as a sterile solution intended solely for parenteral (intravenous use), which facilitates its precise introduction into the systemic circulation.

Composition and Role of the Indium-111 Oxine Complex

The active core of the preparation is the Indium (^111In) Oxyquinoline complex. This is formed by binding the radionuclide Indium-111 (^111In) to the carrier molecule Oxyquinoline (Oxine) to create a lipid-soluble chelated complex. The Indium-111 isotope is vital because it possesses a measured physical half-life of 67.2 hours, allowing flexibility for diagnostic scheduling, and decays by emitting gamma photons, which specialized imaging equipment can detect. The formulation is an aqueous solution, specifically buffered with components like HEPES buffer and sodium chloride solution, to maintain its stability and biological compatibility before use in the specialized cell labeling procedure.

General Purpose: Locating Internal Activity

The general purpose of Indium (^111In) Oxyquinoline is to allow clinicians to precisely localize abscesses, infections, and generalized inflammatory processes inside the body. It achieves this by acting as an agent for cell labeling, a process where it is used to tag a patient's own autologous leukocytes (white blood cells) in a laboratory setting before they are reintroduced. Once these leukocytes are labeled, they retain their natural function of migration to sites of inflammation or infection, enabling their movement to be tracked using a gamma camera for crucial diagnostic imaging. This application provides essential data when investigating the source of unexplained fever or suspected deep-seated infection.

Regulatory References

FDA Label/Package Insert

What side effects are possible with Indium?

Possible Side Effects and Safety Information for Indium

The safety profile for elemental Indium and its compounds is primarily documented in governmental regulatory and occupational health contexts, concerning inhalation exposure to dusts or fumes rather than standard therapeutic use. As such, adverse reaction frequencies (e.g., common, rare) based on clinical trials are not applicable.

Key Safety Considerations (Occupational Exposure)

System-Organ Class	Clinically Significant Adverse Reactions
Respiratory System	Serious, potentially fatal, lung damage (e.g., interstitial lung disease, pulmonary alveolar proteinosis) following chronic inhalation of dusts or fumes (e.g., Indium-Tin Oxide).
Systemic/Other Organs	Damage to the liver and kidneys has been reported following exposure to very high levels. Exposure to specific compounds like Indium Phosphide and Indium Arsenide has been linked to testicular damage and potential carcinogenicity in animal studies, classifying them as Group 2A (Probably carcinogenic to humans) and Group 2B (Possibly carcinogenic to humans) by authoritative international agencies.
Local/Acute Effects	Irritation of the eyes, skin, and respiratory tract (coughing, wheezing, shortness of breath) may occur upon acute exposure.

Safety-Related Restrictions and Monitoring

Official regulatory bodies (e.g., NIOSH, ACGIH) establish Workplace Exposure Limits (typically 0.1 mg/m^3 as a Time-Weighted Average for Indium compounds) to minimize health risks. Exposure at levels exceeding these limits is associated with increased hazard.

High-level safety monitoring notes include recommendations for lung function tests and liver/kidney function tests for individuals with frequent or high occupational exposure. The primary hazard classification is based on the Globally Harmonized System (GHS), labeling the substance or its compounds as causing damage to organs (Lungs) through prolonged or repeated exposure if inhaled.

Overdose and Emergency Response

Overdose and When to Seek Help

Indium-111 Chloride is a radioactive precursor that is not intended for direct human administration; it is used solely as an ingredient to radiolabel other diagnostic agents. Consequently, the primary concern in the event of an overdose or incorrect use is excessive radiation exposure to the patient, which would increase the long-term radiation burden to tissues and organs.

Documented Overdose-Related Risks

Serious, even fatal, systemic outcomes have been officially documented in relation to the use of final, Indium-111 labeled radiopharmaceuticals administered to patients. These severe adverse events have included death and septic meningitis following administration of certain Indium-111 final products (e.g., Pentetate Indium Disodium In 111).

Emergency Actions

If an overdose is suspected, or if the product was accidentally or incorrectly administered, immediate medical attention is required. Patients or caregivers should contact a poison control center or seek medical care right away. In the event of a radiation overexposure, supportive measures are initiated to minimize radiation dose, which may include hydration to encourage the rapid elimination of the radioactive substance from the body. Because the product is administered in a specialized medical setting, overdose is considered unlikely, but all potential severe adverse reactions must be treated with urgency.

Therapeutic Uses of Indium

What Indium (^111In) Oxyquinoline Treats: Main Uses and Benefits

The fundamental purpose of Indium (^111In) Oxyquinoline is to provide essential diagnostic information that is important for guiding the management of serious conditions. It achieves this by localizing the source of inflammation or infection, offering information that guides steps toward managing the condition and achieving symptomatic relief.

This diagnostic procedure is commonly used across conditions presenting with systemic or localized discomfort, primarily when the source of infection is not clear. It is relevant for managing symptoms that create noticeable physiological strain in key clinical contexts, including the investigation of Fever of Unknown Origin (FUO), suspected osteomyelitis (bone infection), prosthetic joint infection, and localizing intra-abdominal abscesses.

This process supports physicians in making necessary treatment adjustments, which may contribute to improved comfort during periods of heightened symptoms. “This diagnostic clarity may offer necessary information to confirm the suspected location of a hidden infection.”

Quick Fact: Relief for Diagnostic Uncertainty The essential benefit provided is the precise localization of pathology, which transforms vague symptom clusters (like unexplained fever) into a confirmed anatomical target. This clarity is important for allowing targeted therapy, which supports the patient during difficult episodes by easing distress and helps maintain a sense of stability.

Regulatory References

NIH MedlinePlus overview of the Indium-labeled White Blood Cell Scan

Eligibility and Restrictions for Use

Who Can and Cannot Use Indium left(^111 In

ight) Oxyquinoline?

This diagnostic radiopharmaceutical's use is governed by regulatory eligibility rules that define both absolute prohibitions and conditional restrictions across specific patient populations. The standard labeled population for established safety and utility is adults, provided the procedure utilizes the patient's own autologous leukocytes.

Classification	Eligibility Status
Contraindication	Prohibited for patients with a known hypersensitivity to the active substance, excipients, or any components of the final preparation.
Pregnancy	Not Recommended. Use is restricted to imperative investigations due to the potential for the radiation to cause fetal harm.
Lactation	Restricted. Breastfeeding must be interrupted after administration, and all expressed milk must be discarded.
Pediatric Use	Not Established. Safety and effectiveness have not been formally established in pediatric patients; activity must be adjusted to the lowest dose achievable.
Geriatric Use	Caution Advised. Data is insufficient to determine if subjects over 65 respond differently; cautious dose selection is necessary.

Caution is also required for patients presenting with severely impaired renal function due to the agent's primary route of elimination.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Indium left(^111 In ight) Oxyquinoline focuses primarily on interactions that may affect the diagnostic efficacy of the labeled white blood cell scan, rather than altering the systemic exposure of the radiopharmaceutical itself.

Pharmacodynamic Interaction Profile

The primary documented interactions are pharmacodynamic, involving medicine classes that can affect the biological function essential for the diagnostic procedure:

Corticosteroids: The co-administration of corticosteroids has been reported to potentially reduce the uptake of the left(^111 In ight)-labeled leukocytes into an abscess site. This effect can impair the sensitivity of the scan, as described in regulatory documentation.
Antibiotics: Antibiotics, particularly those successful in treating an infection, may potentially impair the migration of labeled leukocytes. This occurs by reducing the natural chemotactic stimulus that draws the white blood cells to the infection, leading to reduced diagnostic uptake.

Regulatory Status of Other Interactions

The regulatory labeling for this diagnostic agent is characterized by the absence of other common interaction types:

Contraindicated Combinations: No formal contraindicated medicinal product combinations are explicitly listed in official regulatory documents.
Pharmacokinetic Interactions: Official labeling does not document any interactions related to cytochrome P450 (CYP) enzymes, drug transporters, or other mechanisms that would alter the systemic clearance or plasma concentration of Indium left(^111 In ight) Oxyquinoline.
Food and Timing Rules: No interactions with food, alcohol, herbal products, or specific timing-based separation requirements for co-administered medicines are documented.

The overall interaction structure is defined by its functional interference, while formal pharmacokinetic interactions are not stated in the official regulatory prescribing information.

Mechanism of Action

How Indium left(^111 In

ight) Oxyquinoline Works

U0001f52c Molecular Transport and Intracellular Trapping

The mechanism begins with the Indium-111 left(^111 In ight) Oxyquinoline complex leveraging its lipid solubility to passively diffuse across the membrane of target leukocytes (white blood cells). Once inside, the left(^111 In ight) radionuclide separates from the Oxyquinoline carrier and is permanently trapped by binding to high-affinity cytoplasmic proteins. The resultant intracellular trapping ensures the long-term retention of the diagnostic signal, which is necessary for tracking the cell's natural movement throughout the body.

U0001f9ed Targeted Immune Cell Chemotaxis

The tracking mechanism is functionally dependent on the labeled leukocytes retaining their full chemotactic function—their ability to detect and migrate along chemical gradients (chemokines) released at sites of pathology. As these cells circulate, this functional integrity allows them to perform extravasation and accumulate specifically at the focal site of inflammation. This accumulation concentrates the left(^111 In ight) radionuclide, whose decay produces gamma photons that are then detected by external imaging equipment to localize the activity.

U0001f6a0 Mechanism Constraints

The efficiency of this labeling process is subject to biological constraints. Plasma competition from proteins like transferrin can reduce the amount of left(^111 In ight) available to enter the target cells, potentially weakening the diagnostic signal. Additionally, some non-specific uptake by other circulating cells, such as platelets, can introduce background activity, limiting the clarity and specificity of the tracking mechanism.

Dosage and Administration Information

The use of Indium (^111In) Oxyquinoline is defined by guidelines as a specialized, two-step diagnostic procedure involving the ex vivo (external) labeling of the patient's own white blood cells. This agent is classified as a radiopharmaceutical precursor and is not administered directly to humans.

The official instructions mandate that the solution must first be used for the aseptic, in vitro radiolabeling of a patient’s autologous leukocytes. The final product administered to the patient is the Indium (^111In) labeled cell suspension.

Official Administration Guidelines

The administration of the labeled cells occurs via a single, one-time intravenous injection. The standard adult dosing range for the labeled cells is 7.4 to 18.5 MBq (or 200 to 500 mu Ci). For pediatric patients, the administered dose must be adjusted according to body surface area, weight, or age, with a minimum dose set at 10% of the adult dose to ensure image quality.

The entire process must take place in a specialized Nuclear Medicine setting under the supervision of personnel authorized to handle radioactive medicinal products. A critical procedural condition is that the final labeled cell suspension must be administered within 2 hours of the completion of the in vitro labeling procedure.

Following the injection, diagnostic imaging is typically performed at specific intervals, commonly at 4 to 6 hours and again at 24 hours post-administration. This detailed protocol defines the usage as a single, scheduled diagnostic procedure performed under expert supervision.

Recent Clinical Evidence

Research Evidence for Indium (^111In) Oxyquinoline

This overview summarizes the available research evidence on Indium (^111In) Oxyquinoline, a diagnostic radiopharmaceutical used to label white blood cells, focusing on the context and limitations of the studies conducted by researchers.

Evidence Summary for Localization of Deep-Seated Infections

Research exploring the use of the radiolabeled white blood cell scan to find hidden sites of inflammation, such as abscesses inside the abdomen or pelvis, has mainly been conducted through observational studies and retrospective reviews (analyzing existing patient data).

Researchers studied adult patients suspected of having a serious infection. The primary outcomes examined were the scan's diagnostic accuracy, which means how often the images matched the final diagnosis confirmed by surgical findings or lab cultures.

Studies describe patterns related to the scan's ability to localize sites where white blood cells accumulated. However, the findings also indicate that areas of high normal cell accumulation, such as the liver and spleen, may obscure nearby sites of accumulation. Furthermore, the evidence is limited in its ability to clearly differentiate between infectious and non-infectious causes of inflammation.

Research on Bone and Joint Infection Scenarios

Studies Addressing Prosthetic Joint Infection

For patients with an artificial joint (such as a hip or knee replacement), studies explored the diagnostic challenge of determining whether the joint failure was related to infection or other non-infectious issues like mechanical loosening.

Research involved adult patients presenting with symptoms. Studies examined how the scan performed, sometimes combined with other imaging, to assess diagnostic clarity. The findings across studies were mixed regarding the scan's diagnostic performance in this population.

Current Evidence Gaps and Areas of Uncertainty

A key limitation reported in the research is that the scan localizes white blood cells, which accumulate in both infection and non-infectious inflammation. The scan can indicate a site of pathology, but evidence suggests it is limited in determining the precise cause. Additionally, the evidence quality varies across studies, and there is limited information for characterizing the long-term stability or consistency of results over extended periods.

Key Studies & References

NIH MedlinePlus: White blood cell scan

Frequently Asked Questions (FAQ)

Common questions about Indium (FAQ)

Q: How long does it take to feel any effects from Indium?

A: Indium (^111In) Oxyquinoline is a diagnostic agent, not a therapeutic drug, meaning it is not intended to create a subjective feeling or effect. The procedure is designed to provide visual information to clinicians. For this reason, diagnostic images are typically captured at specific intervals, such as 4 to 6 hours and again at 24 hours, after the labeled cells are injected.

Q: What is the scientific evidence supporting the health claims about Indium?

A: Regulatory evidence supports the use of Indium (^111In) Oxyquinoline exclusively as a diagnostic radiopharmaceutical for localizing inflammatory processes and infection sites in the body. Official sources do not contain evidence supporting its use for general health, anti-aging, or supplement-related claims.

Q: What are the long-term effects of using Indium?

A: The possibility of delayed adverse reactions following the use of this diagnostic agent has not been extensively studied in clinical trials. As the procedure involves exposure to ionizing radiation, official information notes a potential, small risk of long-term biological effects. Potential radiation risks are generally considered by the medical team to be outweighed by the value of the essential diagnostic information provided.

Q: What are the most common mild side effects reported for Indium?

A: Adverse reaction frequencies (like common or rare) are not well-established for this specialized diagnostic agent. However, documented side effects from official sources may include fever, skin reactions (such as rash, itching, or hives), and may include hypersensitivity or severe allergic reactions.

Q: Are the side effects of Indium more pronounced at higher intakes?

A: Official information provides general procedures for managing accidental overdose. Since the body naturally clears the labeled white blood cells, there is little supportive treatment that can accelerate the elimination of the radionuclide in case of an overdose.

Q: What is the maximum duration people usually take Indium for?

A: Indium (^111In) Oxyquinoline is administered as a single, one-time intravenous injection of the labeled cells for a scheduled diagnostic procedure. It is not intended for continuous or repeated therapeutic use like a daily medication.

Q: Can Indium cause any stomach issues like nausea or indigestion?

A: Official labeling for this specific radiopharmaceutical does not list nausea or indigestion as common adverse reactions. However, some patients have reported experiencing nausea and vomiting with other diagnostic radiopharmaceuticals.

Q: Is it normal to feel a metallic taste after taking Indium?

A: Official product information for Indium (^111In) Oxyquinoline does not specifically list a metallic taste as a reported side effect.

Q: Can Indium be taken alongside thyroid medication?

A: Official regulatory documents do not list any formal pharmacokinetic interactions, such as those related to the metabolism or clearance of other medicines. Only corticosteroids and certain antibiotics are mentioned as potentially impacting the quality of the diagnostic scan.

Q: Does Indium affect sleep patterns?

A: Official regulatory documents do not report or document effects of Indium (^111In) Oxyquinoline on sleep patterns.

Q: How often should Indium be taken for it to be effective?

A: This product is a diagnostic agent administered as a single, one-time injection of labeled cells in a hospital setting. It is not a medication that requires repeated or daily dosing to maintain a therapeutic effect.

Q: Is there a difference in effectiveness between liquid and capsule forms of Indium?

A: The regulated medical product, Indium (^111In) Oxyquinoline, is supplied only as a sterile solution for the intravenous radiolabeling of cells. There are no approved capsule or oral liquid forms of this specific diagnostic agent.

Q: Is 'Indium sulfate' the same as just 'Indium' in supplements?

A: The regulated medical product is a specialized radiochemical complex known as Indium (^111In) Oxyquinoline. The official regulatory label does not include any information or comparisons related to 'Indium sulfate' or 'elemental Indium' found in supplements.

Q: How is Indium absorbed by the body?

A: The Indium-111 is not absorbed in the traditional sense of ingesting a pill. The mechanism involves the lipid-soluble complex diffusing across the white blood cell membrane, where the Indium-111 is then trapped inside the cell by binding to cytoplasmic proteins.

Q: Does taking Indium with food increase or decrease its absorption?

A: Since this product is administered as a sterile, intravenous injection of labeled cells, it is not taken orally, and therefore, official labeling states no interactions with food or alcohol are documented.

Q: Is it possible to take too much Indium?

A: Official information outlines procedures to follow in the event of an accidental overdose of the labeled cells. Because the body eliminates the radionuclide through the natural breakdown of the cells, very little supportive treatment can be done to hasten its clearance.

Q: What happens if I forget to take my Indium dose for a day?

A: This product is administered as a single, one-time injection as part of a scheduled diagnostic procedure. It is not a daily therapeutic medicine, so there is no concern about 'forgetting' a dose.

Q: Do people with autoimmune conditions need to be careful with Indium?

A: The only absolute contraindication listed in official regulatory documents is a known hypersensitivity (allergy) to the active substance or any of its components. Autoimmune conditions are not listed as a formal contraindication.

Q: Why do some people experience initial fatigue when starting Indium?

A: General feelings of malaise or fatigue may sometimes be reported after the injection procedure, though this is usually temporary. However, the regulatory label does not detail fatigue as a common adverse reaction specific to the drug.

Q: Does Indium interact with caffeine or alcohol?

A: The official labeling states that no interactions with food, alcohol, or herbal products are documented for this diagnostic agent.

Q: Are there any human clinical trials on the benefits of Indium?

A: Clinical studies are mainly in the form of observational studies and retrospective reviews designed to assess the scan's ability to localize infections and inflammatory processes. There is no available clinical data to support therapeutic health benefits.

Q: Has any research been done on Indium for bone health?

A: Research has been conducted on the scan's use for detecting infection in bone and joint scenarios, such as prosthetic joint infections. However, this research focuses on diagnosis and does not provide evidence for general bone health or density.

Q: Are there different forms of Indium compounds used in medicine besides the sulfate?

A: The regulated compound used for cell labeling is Indium (^111In) Oxyquinoline. Other forms of Indium radiopharmaceuticals are approved for different diagnostic uses, such as Indium-111 Pentetreotide.

How should Indium be stored and disposed of?

The storage and disposal of Indium left(^111 In ight) Oxyquinoline are strictly controlled due to its classification as a Diagnostic Radiopharmaceutical.

Storage Requirements

Official labeling requires the product to be stored at room temperature, typically between 15 C and 30 C (59 F and 86 F). It is explicitly required not to freeze the solution. Adequate radiation shielding (e.g., lead) must be maintained at all times. The vial is intended for single use only and must be kept out of the sight and reach of children.

Disposal Instructions

Unused product and waste must be disposed of in accordance with local, state, and federal regulations for radioactive materials. Disposal must follow procedures established by a Radiation Safety Program and must not be mixed with household trash.

Indium